Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Assets (2020 - 2025)

Apellis Pharmaceuticals has reported Assets over the past 6 years, most recently at $1.1 billion for Q4 2025.

  • Quarterly results put Assets at $1.1 billion for Q4 2025, up 21.49% from a year ago — trailing twelve months through Dec 2025 was $1.1 billion (up 21.49% YoY), and the annual figure for FY2025 was $1.1 billion, up 21.49%.
  • Assets for Q4 2025 was $1.1 billion at Apellis Pharmaceuticals, up from $1.1 billion in the prior quarter.
  • Over the last five years, Assets for APLS hit a ceiling of $1.1 billion in Q1 2022 and a floor of $525.7 million in Q3 2021.
  • Median Assets over the past 5 years was $877.3 million (2021), compared with a mean of $874.3 million.
  • Biggest five-year swings in Assets: plummeted 31.58% in 2021 and later surged 66.05% in 2022.
  • Apellis Pharmaceuticals' Assets stood at $881.8 million in 2021, then fell by 13.78% to $760.2 million in 2022, then rose by 3.75% to $788.7 million in 2023, then increased by 12.21% to $885.1 million in 2024, then grew by 21.49% to $1.1 billion in 2025.
  • The last three reported values for Assets were $1.1 billion (Q4 2025), $1.1 billion (Q3 2025), and $821.4 million (Q2 2025) per Business Quant data.